Morgan Stanley reinstates coverage of this controversial used-car play
The firm resumed coverage of Carvana, citing “improved confidence.” The stock could see a wide range of outcomes from here, analyst Adam Jonas said.
Stashing cash: 71% of Americans are setting more money aside amid recession fears, new report finds
Depending on how accessible you need your savings to be, here are some of the best ways to earn interest on your emergency money.
Homebuilder sentiment pulls out of negative territory for the first time in nearly a year
It’s the fifth straight month of gains and the first reading of builder sentiment since July that wasn’t negative.
Retail sales rose 0.4% in April, less than expected as consumers struggle with inflation
Excluding auto-related figures, sales increased 0.4%, which was in line with expectations.
OpenAI CEO Sam Altman testifies before U.S. Senate: live
OpenAI CEO Sam Altman is testifying before the U.S. Senate Judiciary Committee on AI oversight and regulation. Watch live here.
Sam Altman wows lawmakers at closed AI dinner: ‘Fantastic…forthcoming’
Lawmakers had a dinner discussion with OpenAI CEO Sam Altman. It comes at a peak moment for AI, which has thoroughly captured Congress’ fascination.
FTC sues to block Amgen acquisition of Horizon Therapeutics
Amgen wants to buy Horizon Therapeutics to bolster is drug portfolio as it faces patent expirations. The FTC fears the deal could entrench monopoly positions.
This medtech company’s shares could jump 20%, Oppenheimer says
GE Healthcare completed a spinoff from its parent company earlier in 2023. Oppenheimer initiated coverage with an overweight rating
Google Cloud launches A.I.-powered tools to accelerate drug discovery, precision medicine
The solutions mark Google’s latest advancements in the AI arms race and hope to address a long-standing issue facing biotech and pharmaceutical companies.
BMO Capital Markets says this biotech company is ‘best-in-class,’ sees shares surging more than 25%
The firm upgraded shares to outperform from market perform and raised its price target to $100 from $90. The new price target implies shares rallying 27.5%.
